



(12) Translation of
European patent specification

(11) NO/EP 3241843 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/22 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.11.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.07.28
(86)	European Application Nr.	17161990.1
(86)	European Filing Date	2009.06.25
(87)	The European Application's Publication Date	2017.11.08
(30)	Priority	2008.06.25, US, 75692 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP2307455, 2009.06.25
(73)	Proprietor	Novartis AG, Lichtstrasse 35, 4056 Basel, Sveits
(72)	Inventor	BORRAS, Leonardo, c/o Novartis AG Lichtstrasse 35, 4056 Basel, Sveits URECH, David, c/o Novartis AG Lichtstrasse 35, 4056 Basel, Sveits
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **SOLUBILITY OPTIMIZATION OF IMMUNOBINDERS**

(56) References
Cited:

US-B1- 6 815 540
DAVIES J ET AL: "SINGLE ANTIBODY DOMAINS AS SMALL RECOGNITION UNITS: DESIGN
AND IN VITRO ANTIGEN SELECTION OF CAMELIZED, HUMAN VH DOMAINS WITH
IMPROVED PROTEIN STABILITY", PROTEIN ENGINEERING, OXFORD UNIVERSITY
PRESS, SURREY, GB, vol. 9, no. 6, 1 January 1996 (1996-01-01) , pages 531-537,
XP000971767, ISSN: 0269-2139
NIEBA L ET AL: "Disrupting the hydrophobic patches at the antibody variable/constant domain
interface: Improved in vivo folding and physical characterization of an engineered scFv
fragment", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 10,
no. 4, 1 January 1997 (1997-01-01), pages 435-444, XP002249462, ISSN: 0269-2139
DAVIES J ET AL: "'Camelising' human antibody fragments: NMR studies on VH domains", FEBS
LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 339, no. 3, 21 February 1994 (1994-02-21),
pages 285-290, XP025614903, ISSN: 0014-5793 [retrieved on 1994-02-21]
JUNG S ET AL: "Selection for improved protein stability by phage display", JOURNAL OF
MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19),
pages 163-180, XP004461860, ISSN: 0022-2836

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Immunobinder omfattende det følgende løselighetsfremmende motivet i aminosyreposisjon 12, 103 og 144 i tungkjeden (AHO-nummerering):

5

(a1) serin (S) i aminosyreposisjon 12 i tungkjeden;

(b1) treonin (T) i aminosyreposisjon 103 i tungkjeden; og

(c1) serin (S) i aminosyreposisjon 144 i tungkjeden; eller

(a2) serin (S) i aminosyreposisjon 12 i tungkjeden;

(b2) treonin (T) i aminosyreposisjon 103 i tungkjeden; og

10

(c2) treonin (T) i aminosyreposisjon 144 i tungkjeden,

hvor immunobinderen er et scFv-antistoff, et fullengde immunglobulin eller en nanobody.

2. Immunobinderen ifølge krav 1, hvor immunobinderen spesifikt binder til human TNF α eller til human VEGF.

15

3. Sammensetning omfattende immunobinderen ifølge krav 1 eller 2 og en farmasøytisk akseptabel bærer.